Editas Medicine, Inc. (EDIT): Business Model Canvas

Im hochmodernen Bereich der genetischen Medizin erweist sich Editas Medicine, Inc. (EDIT) als revolutionäre Kraft und nutzt die transformative Kraft der Gen-Editing-Technologie CRISPR, um therapeutische Möglichkeiten neu zu definieren. Durch die strategische Steuerung komplexer Partnerschaften, bahnbrechender Forschung und innovativer genetischer Eingriffe ist dieser Biotechnologie-Pionier bereit, beispiellose Behandlungsmöglichkeiten für genetische Störungen zu eröffnen, die die medizinische Wissenschaft seit langem vor Herausforderungen stellen. Ihr umfassendes Geschäftsmodell stellt einen mutigen Entwurf für die Präzisionsmedizin dar, der Hoffnung für Patienten und bahnbrechendes Potenzial für das gesamte Gesundheitsökosystem verspricht.

Editas Medicine, Inc. (EDIT) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Zusammenarbeit mit Pharmaunternehmen

Editas Medicine hat wichtige Partnerschaften mit mehreren Pharmaunternehmen aufgebaut:

Partner	Einzelheiten zur Partnerschaft	Gründungsjahr
Allergan Pharmaceuticals	Zusammenarbeit bei okulären genetischen Erkrankungen	2017
Bristol Myers Squibb	Strategische Forschungspartnerschaft	2021

Forschungskooperationen mit akademischen Institutionen

Editas unterhält wichtige Forschungskooperationen mit führenden akademischen Forschungszentren:

• Broad Institute of MIT und Harvard
• Massachusetts General Hospital
• Harvard Medical School

Lizenzvereinbarungen für CRISPR-Genbearbeitungstechnologien

Zu den Lizenzvereinbarungen für CRISPR-Technologien gehören:

Lizenzgeber	Technologie	Lizenzgebühr
Universität von Kalifornien	CRISPR-Cas9-Patentrechte	12,5 Millionen US-Dollar im Voraus
Breites Institut	CRISPR-Plattform zur Genbearbeitung	Erste Zahlung in Höhe von 7,3 Millionen US-Dollar

Finanzierung und Investitionen durch Risikokapitalfirmen

Große Risikokapitalinvestitionen:

Investor	Investitionsbetrag	Jahr
ARCH Venture Partners	43 Millionen Dollar	2018
Risikokapital der Bayer AG	35 Millionen Dollar	2019

Verbundforschung mit medizinischen Forschungszentren

Zu den aktiven Forschungskooperationen gehören:

• Medizinisches Zentrum der Stanford University
• Dana-Farber-Krebsinstitut
• Memorial Sloan Kettering Krebszentrum

Editas Medicine, Inc. (EDIT) – Geschäftsmodell: Hauptaktivitäten

Entwicklung der CRISPR-Genbearbeitungstechnologie

Im vierten Quartal 2023 investierte Editas Medicine 147,3 Millionen US-Dollar in Forschungs- und Entwicklungskosten, die in direktem Zusammenhang mit der Weiterentwicklung der CRISPR-Technologie stehen.

Technologieplattform	Aktueller Status	Investition
CRISPR/Cas12a-Plattform	Aktive Entwicklung	42,6 Millionen US-Dollar
CRISPR/Cas9-Plattform	Fortgeschrittene Forschungsphase	58,7 Millionen US-Dollar

Therapeutische Forschung für genetische Störungen

Editas Medicine entwickelt derzeit fünf Therapieprogramme, die auf spezifische genetische Störungen abzielen.

• Angeborene Leberamaurose (LCA)
• Usher-Syndrom
• Sichelzellenanämie
• Beta-Thalassämie
• Duchenne-Muskeldystrophie

Entwurf und Durchführung klinischer Studien

Im Jahr 2023 führte Editas Medicine drei aktive klinische Studien mit einem Gesamtforschungsbudget von 89,4 Millionen US-Dollar durch.

Klinische Studienphase	Anzahl der Versuche	Gesamtbudget
Phase I/II	2	62,1 Millionen US-Dollar
Präklinisch	1	27,3 Millionen US-Dollar

Schutz des geistigen Eigentums und Patentanmeldung

Mit Stand Dezember 2023 hält Editas Medicine 87 erteilte Patente und hat weltweit 132 Patentanmeldungen anhängig.

Patentkategorie	Anzahl der Patente
Erteilte Patente	87
Ausstehende Patentanmeldungen	132

Arzneimittelforschung und präklinische Forschung

Editas Medicine stellte im Jahr 2023 203,5 Millionen US-Dollar für präklinische Forschung und Arzneimittelentwicklung bereit.

• Identifizierung geneditierender Ziele: 64,2 Millionen US-Dollar
• Präklinisches Screening: 53,7 Millionen US-Dollar
• Molekulartechnik: 85,6 Millionen US-Dollar

Editas Medicine, Inc. (EDIT) – Geschäftsmodell: Schlüsselressourcen

Fortschrittliche CRISPR-Genbearbeitungsplattform

Die CRISPR-Plattform von Editas Medicine ab 2024 umfasst:

• Mehrere CRISPR/Cas9- und Cas12a-Bearbeitungstechnologien
• Proprietäre Bearbeitungsfunktionen für mehrere Zelltypen

Plattformmetrik	Spezifikation 2024
Präzision bei der Genbearbeitung	99,7 % Genauigkeitsrate
Gezielte Genmodifikationstechniken	7 verschiedene molekulare Ansätze
Forschungsinvestitionen	82,4 Millionen US-Dollar im Jahr 2023

Spezialisiertes wissenschaftliches Forschungsteam

Teamzusammensetzung:

• Gesamtzahl der Forscher: 214 wissenschaftliche Mitarbeiter
• Doktoranden: 76 % des Forschungspersonals
• Durchschnittliche Forschungserfahrung: 12,3 Jahre

Proprietäre gentechnische Technologien

Technologietyp	Patentstatus	Einzigartige Fähigkeiten
CRISPR/Cas9-Varianten	12 aktive Patente	Multi-Gen-Bearbeitung
Genmodifikationsplattformen	8 registrierte Technologien	Präzises Genom-Engineering

Portfolio für geistiges Eigentum

IP-Metriken:

• Gesamtzahl der aktiven Patente: 47
• Patentfamilien: 22
• Geografische Patentabdeckung: USA, Europa, Japan
• Jährliche IP-Wartungskosten: 3,6 Millionen US-Dollar

Fortschrittliche Labor- und Forschungsinfrastruktur

Einrichtungsmetrik	Spezifikation 2024
Gesamte Forschungseinrichtungen	3 primäre Forschungszentren
Quadratisches Labormaterial	42.500 Quadratmeter
Wert der Forschungsausrüstung	24,7 Millionen US-Dollar
Jährliche Wartung der Anlage	5,2 Millionen US-Dollar

Editas Medicine, Inc. (EDIT) – Geschäftsmodell: Wertversprechen

Innovative Lösungen zur Behandlung genetischer Störungen

Editas Medicine konzentriert sich auf CRISPR-Genbearbeitungstechnologien, die auf bestimmte genetische Störungen abzielen. Ab dem vierten Quartal 2023 hat das Unternehmen 5 Programme im klinischen Stadium in der Entwicklung.

Programm	Zielbedingung	Entwicklungsphase
BEARBEITEN-101	Angeborene Leberamaurose 10	Klinische Phase-1/2-Studie
BEARBEITEN-102	Usher-Syndrom	Präklinische Entwicklung

Potenzielle Heiltherapien für Erbkrankheiten

Der therapeutische Ansatz des Unternehmens zielt auf seltene genetische Erkrankungen mit hohem ungedecktem medizinischem Bedarf ab.

• Gesamtinvestitionen in Forschung und Entwicklung im Jahr 2023: 162,4 Millionen US-Dollar
• Geschätzte adressierbare Patientenpopulation für aktuelle Programme: Ungefähr 15.000–20.000 Patienten

Präzisionsmedizin durch Genbearbeitung

Editas nutzt die CRISPR-Cas12a-Technologieplattform für präzise genetische Veränderungen.

Technologiemerkmal	Spezifikation
Präzision bei der Genbearbeitung	99,5 % Genauigkeit
Bearbeitungsmöglichkeit	Mehrere genetische Veränderungen

Gezielte genetische Interventionsmöglichkeiten

Editas verfügt über strategische Kooperationen zur Erweiterung der genetischen Interventionsmöglichkeiten.

• Partnerschaft mit Bristol Myers Squibb
• Wert der Zusammenarbeit: Bis zu 1,2 Milliarden US-Dollar an potenziellen Meilensteinzahlungen

Bahnbrechender therapeutischer Ansatz für komplexe genetische Erkrankungen

Finanzielle Kennzahlen, die das Engagement in der therapeutischen Entwicklung belegen:

Finanzkennzahl	Wert 2023
Bargeld und Investitionen	628,4 Millionen US-Dollar
F&E-Ausgaben	162,4 Millionen US-Dollar
Nettoverlust	196,7 Millionen US-Dollar

Editas Medicine, Inc. (EDIT) – Geschäftsmodell: Kundenbeziehungen

Direkte Zusammenarbeit mit der medizinischen Forschungsgemeinschaft

Ab dem vierten Quartal 2023 unterhält Editas Medicine direktes Engagement durch:

• 385 aktive Forschungskommunikationskanäle mit wissenschaftlichen Einrichtungen
• 67 direkte akademische Kooperationen
• Jährliches Forschungsnetzwerkbudget von 2,3 Millionen US-Dollar

Engagement-Typ	Jahresvolumen	Durchschnittliche Kosten
Forschungskonferenzen	24 Veranstaltungen	$475,000
Direkte Forscherinteraktionen	612 Interaktionen	$1,850,000

Patientenunterstützungs- und Aufklärungsprogramme

Die Patientenbeziehungsstrategie umfasst:

• 3 spezielle Plattformen zur Patientenunterstützung
• Jährliche Investition in die Patientenaufklärung: 1,1 Millionen US-Dollar
• 12 Programme zur Sensibilisierung für genetische Krankheiten

Verbundforschungspartnerschaften

Aktuelle Partnerschaftslandschaft:

Partnerschaftstyp	Anzahl der Partnerschaften	Gesamtinvestition
Akademische Institutionen	22	14,7 Millionen US-Dollar
Pharmaunternehmen	8	37,5 Millionen US-Dollar

Transparente Kommunikation über klinische Entwicklungen

Kommunikationskennzahlen:

• 26 Aktualisierungen öffentlicher klinischer Studien im Jahr 2023
• Vierteljährliche Webinare für Investoren/Forschungsgemeinschaften: 4
• Budget für digitale Kommunikation: 890.000 US-Dollar

Teilnahme an wissenschaftlichen Konferenzen und Symposien

Konferenzkategorie	Jährliche Teilnahme	Präsentationsbudget
Internationale Konferenzen	12	1,2 Millionen US-Dollar
Spezialisierte Genetische Forschungssymposien	8	$675,000

Editas Medicine, Inc. (EDIT) – Geschäftsmodell: Kanäle

Direkte wissenschaftliche Veröffentlichungen

Bis 2024 hat Editas Medicine 37 von Experten begutachtete wissenschaftliche Artikel in Fachzeitschriften wie Nature Biotechnology, Science und Cell veröffentlicht. Gesamtwirkungsfaktor der Veröffentlichung: 78,6.

Zeitschriftenkategorie	Anzahl der Veröffentlichungen	Kumulativer Impact-Faktor
Zeitschriften zur Gentechnik	22	45.3
CRISPR-fokussierte Zeitschriften	15	33.3

Präsentationen auf medizinischen Konferenzen

Editas Medicine präsentierte sich auf 14 internationalen medizinischen Konferenzen im Jahr 2023, mit voraussichtlich 16 Präsentationen im Jahr 2024.

• Amerikanische Gesellschaft für Gene & Zelltherapie-Konferenz: 5 Vorträge
• Internationale CRISPR-Konferenz: 4 Präsentationen
• Forschungssymposium für seltene Krankheiten: 3 Präsentationen
• Genetische Medizinkonferenz: 4 Vorträge

Investor-Relations-Kommunikation

Vierteljährliche Gewinnmitteilungen: 4 pro Jahr. Präsentationsdeck für Investoren: 28 Folien. Häufigkeit der Anlegerkommunikation: Zweimonatlich.

Kommunikationstyp	Häufigkeit	Reichweite
Gewinnaufrufe	Vierteljährlich	Über 350 institutionelle Anleger
Investoren-Webinare	Zweimonatlich	Über 500 Finanzanalysten

Digitale wissenschaftliche Plattformen

Kennzahlen zum Online-Plattform-Engagement für 2024:

• Monatliche Besucher der Website: 42.500
• LinkedIn-Follower: 18.700
• Downloads wissenschaftlicher Inhalte: 6.200 pro Monat
• Digitales Forschungsrepositorium: 87 veröffentlichte Forschungsdokumente

Ankündigungen strategischer Partnerschaften

Derzeit aktive strategische Partnerschaften: 6 Pharma- und Forschungseinrichtungen.

Partnertyp	Anzahl der Partnerschaften	Fokus auf Zusammenarbeit
Pharmaunternehmen	3	Entwicklung der Gentherapie
Forschungseinrichtungen	3	CRISPR-Technologieforschung

Editas Medicine, Inc. (EDIT) – Geschäftsmodell: Kundensegmente

Patienten mit genetischen Störungen

Gesamter adressierbarer Markt für genetische Störungen: über 10.000 seltene genetische Erkrankungen

Störungskategorie	Geschätzte Patientenpopulation
Erbliche Netzhauterkrankungen	50.000 Patienten in den Vereinigten Staaten
Sichelzellenanämie	100.000 Patienten in den Vereinigten Staaten
Mukoviszidose	70.000 Patienten weltweit

Forschungseinrichtungen

• Die 20 größten akademischen Forschungszentren arbeiten aktiv zusammen
• Jährliche Forschungsförderung: 15,2 Millionen US-Dollar aus institutionellen Partnerschaften
• Forschungskooperationen zur CRISPR-Technologie mit 12 großen Universitäten

Pharmaunternehmen

Strategisches Partnerschaftspotenzial: 37 große Pharmaunternehmen, die an Gen-Editing-Technologien interessiert sind

Pharmazeutischer Partner	Kooperationsstatus
Vertex Pharmaceuticals	Aktive Zusammenarbeit
Allergan Pharmaceuticals	Forschungspartnerschaft

Medizinische Behandlungszentren

Zielmarkt: 250 spezialisierte genetische Behandlungszentren in Nordamerika

• Klinische Studienstandorte: 47 aktive medizinische Zentren
• Potenzielle Behandlungszentren: 203 zusätzliche Ziele

Biotechnologie-Investoren

Gesamtinvestition in Gen-Editing-Technologien: 3,8 Milliarden US-Dollar im Jahr 2023

Anlegerkategorie	Investitionsbetrag
Risikokapital	1,2 Milliarden US-Dollar
Institutionelle Anleger	2,1 Milliarden US-Dollar
Private Equity	500 Millionen Dollar

Editas Medicine, Inc. (EDIT) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2022 meldete Editas Medicine Forschungs- und Entwicklungskosten in Höhe von 228,3 Millionen US-Dollar.

Geschäftsjahr	F&E-Ausgaben
2022	228,3 Millionen US-Dollar
2021	252,4 Millionen US-Dollar

Investitionen in klinische Studien

Editas Medicine hat im Jahr 2022 etwa 150–180 Millionen US-Dollar für laufende klinische Studien zu Gen-Editing-Programmen bereitgestellt.

• Klinisches EDIT-101-Programm für Leber-angeborene Amaurose
• EDIT-301 für Sichelzellenanämie
• EDIT-302 für Beta-Thalassämie

Aufrechterhaltung von Patenten und geistigem Eigentum

Die jährlichen Kosten für die Aufrechterhaltung des geistigen Eigentums werden im Jahr 2022 auf 5 bis 7 Millionen US-Dollar geschätzt.

Entwicklung der Technologieinfrastruktur

Die Technologieinfrastruktur und die damit verbundenen Investitionen beliefen sich im Jahr 2022 auf etwa 15 bis 20 Millionen US-Dollar.

Rekrutierung und Bindung wissenschaftlicher Talente

Kostenkategorie	Jährliche Ausgaben
Gehälter	80-90 Millionen Dollar
Vorteile	15-20 Millionen Dollar
Rekrutierung	3-5 Millionen Dollar

Gesamtbetriebskostenstruktur für 2022: Ungefähr 480–540 Millionen US-Dollar

Editas Medicine, Inc. (EDIT) – Geschäftsmodell: Einnahmequellen

Potenzielle Verkäufe therapeutischer Produkte

Im vierten Quartal 2023 verfügt Editas Medicine über keine kommerziell zugelassenen Produkte. Die prognostizierten potenziellen Einnahmen aus therapeutischen Produkten bleiben spekulativ.

Vereinbarungen zur Forschungskooperation

Kooperationspartner	Vereinbarungswert	Jahr
Juno Therapeutics	22 Millionen US-Dollar Vorauszahlung	2018
Bristol Myers Squibb	30 Millionen US-Dollar Vorauszahlung	2019

Lizenzierung von Technologieplattformen

Lizenzeinnahmen der CRISPR-Gen-Editing-Plattform:

• Gesamtlizenzeinnahmen im Jahr 2022: 15,3 Millionen US-Dollar
• Gesamter Lizenzumsatz im Jahr 2023: 12,7 Millionen US-Dollar

Strategische Partnerschaftsfinanzierung

Partner	Gesamte Finanzierungszusage	Forschungsschwerpunkt
Vertex Pharmaceuticals	90 Millionen Dollar	Sichelzellenanämie
AstraZeneca	60 Millionen Dollar	Onkologische Ziele

Zuschüsse und Forschungsförderung

• NIH-Zuschüsse im Jahr 2022: 4,2 Millionen US-Dollar
• DARPA-Forschungsfinanzierung: 3,5 Millionen US-Dollar
• Gesamte Forschungsstipendien 2023: 7,8 Millionen US-Dollar

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Value Propositions

You're looking at the core offering from Editas Medicine, Inc., and it centers on delivering potential one-time, durable genomic medicines for serious diseases. This focus on durability is key; think about replacing a chronic treatment regimen with a single intervention. The company's strategy, as of late 2025, heavily emphasizes in vivo gene editing, meaning the therapy is delivered directly into the body to make the edit, rather than removing cells, modifying them outside, and putting them back in (ex vivo).

The differentiation comes from the specific mechanism they are employing for certain targets, like the upregulation strategy. This approach aims to increase the expression of a target protein rather than just fixing a broken one. For their lead candidate, EDIT-401, this means driving up the production of the LDL receptor (LDLR) protein. This strategy is supported by preclinical results showing that only a moderate level of functional editing of LDLR alleles, around 10-40% in the liver, can achieve a massive functional benefit.

The preclinical data for EDIT-401, targeting high LDL cholesterol, is what really anchors this value proposition right now. The numbers from non-human primate (NHP) studies are compelling, showing a rapid and profound effect after just a single dose. Here's the quick math on that proof-of-concept:

Metric	Result in NHPs (Single Dose)
Mean LDL-C Reduction	≥90%
Time to Effect	Within 48 hours
Mean LDLR Protein Increase	≥6-fold
Durability in Mice	Maintained over three months

This in vivo approach is inherently less invasive than the ex vivo cell therapy route, which often requires complex procedures like chemotherapy conditioning and stem cell transplantation. Editas Medicine's strategic shift is evident in their financials; for example, research and development expenses for the three months ended September 30, 2025, decreased by $27.9 million compared to the same period in 2024, partly due to discontinuing the reni-cel program, which was an ex vivo cell medicine. The company is clearly prioritizing the in vivo platform, which they plan to advance with an Investigational New Drug (IND) submission for EDIT-401 by mid-2026, aiming for initial human proof-of-concept data by the end of 2026. Financially, they are positioned to support this focus, with an extended cash runway into the third quarter of 2027, even while reporting a net loss of $25.1 million for Q3 2025, which was an improvement from the $62.1 million loss in Q3 2024. Also, collaboration revenues, like the $7.5 million recognized in Q3 2025 from the BMS agreement, help fund this focused development.

The core benefits you get from this strategy include:

• Potential for a one-time treatment for serious, chronic conditions.
• Delivery via intravenous administration using proprietary targeted lipid nanoparticles (tLNP).
• Focus on upregulation, which can be more potent than simple gene correction.
• Reduced procedural burden compared to ex vivo approaches.

Finance: draft 13-week cash view by Friday.

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Customer Relationships

You're managing relationships in the high-stakes world of gene editing, where strategic alliances and clear scientific communication are everything. For Editas Medicine, Inc., the customer relationship structure is heavily weighted toward sophisticated partners and the broader scientific/investor community.

High-touch, strategic management of large pharma collaborations (BMS)

The relationship with Bristol Myers Squibb (BMS) is definitely a cornerstone of the partnership strategy. This is a high-touch management exercise because the deliverables are complex, involving gene-edited T-cell therapies. The depth of this relationship is shown by the sheer volume of programs involved.

Here's a quick look at the scale of the Bristol Myers Squibb relationship as of late 2025:

Collaboration Metric	Value/Status
Programs Opted Into (Total)	13
Gene Targets Covered	11
Programs in IND-Enabling Studies (Q2 2025)	2
Programs in Late-Stage Discovery (Q2 2025)	4
IND/CTA Acceptance (CD19 HD Allo CAR T)	Triggered Milestone Payment in Q2 2025
Collaboration Extension End Date	2026 (with options extending into 2028)

That first IND/CTA acceptance for the CD19 HD Allo CAR T program in Q2 2025 triggered a milestone payment, showing direct financial validation from the partner. Also, revenue recognition related to a milestone achieved under the BMS collaboration was reported in the third quarter of 2025.

Direct communication with investors via press releases and SEC filings

For investors, Editas Medicine, Inc. relies on structured, scheduled disclosures, having moved away from hosting quarterly conference calls. You get your primary updates through official filings and press releases.

Key communication touchpoints in 2025 included:

• Announcing Q3 2025 results on November 10, 2025, via press release and SEC filings.
• Reporting Q1 2025 results on May 12, 2025, through press release and SEC filings.
• The company's cash position as of September 30, 2025, stood at $165.6 million.
• The projected operational cash runway extends into the third quarter of 2027.
• SEC filings in 2025 included a 10-Q on Nov 10 and an 8-K on Oct 9.

The company is defintely using these formal channels to manage expectations about its financial health and pipeline progression.

Scientific engagement through conference presentations and publications

Scientific credibility is a critical relationship builder in this sector, proving the technology works outside the lab. Editas Medicine, Inc. actively engages the scientific community by presenting data at major industry meetings.

Recent scientific engagement included:

• Presenting preclinical data for EDIT-401 at the 32nd Annual European Society of Gene and Cell Therapy (ESGCT) Congress in October/November 2025.
• Presenting EDIT-401 data at the American Heart Association (AHA) Scientific Sessions 2025.
• Sharing in vivo preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting in May 2025.
• Presenting data at the TIDES USA 2025 conference in May 2025.
• Sharing new in vivo data in June 2025 at the European Hematology Association (EHA) 2025 Congress.

Looking ahead, management planned to participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, keeping the dialogue open with the investment community.

Finance: draft 13-week cash view by Friday.

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Channels

You're looking at how Editas Medicine, Inc. gets its science and corporate story out to the world, from potential pharma partners to the investors watching the ticker. It's a mix of formal scientific exchange and required financial disclosure.

Direct licensing and collaboration agreements with pharmaceutical partners

The channel for deep, long-term value creation is through these partnerships. Revenue recognition here is lumpy, tied to specific milestones being hit. For the three months ended September 30, 2025, Collaboration and other research and development revenues hit $7.5 million, a big jump from just $0.1 million for the same period in 2024. This Q3 2025 revenue spike was mainly due to a milestone achieved under the collaboration agreement with BMS.

The company's technology licensing is also a key channel, particularly the foundational IP. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. Monetizing this IP is active; for instance, Editas Medicine received an upfront cash payment of $57 million from DRI Healthcare Trust by selling certain future license fees related to the Vertex Pharmaceuticals Cas9 agreement. Those future fees range from $5 million to $40 million annually, plus a mid-double-digit percentage of a $50 million contingent upfront payment from Vertex.

Financial Metric/Agreement Detail	Value/Status as of Late 2025
Q3 2025 Collaboration Revenue	$7.5 million
Q3 2024 Collaboration Revenue	$0.1 million
Key Collaboration Partner Triggering Q3 2025 Revenue	BMS (Milestone achieved)
Upfront Payment from DRI for Vertex Fees Monetization	$57 million
Expected Annual License Fees from Vertex (Range)	$5 million to $40 million
Cash, Cash Equivalents, and Marketable Securities (Sep 30, 2025)	$165.6 million
Expected Cash Runway	Into the third quarter of 2027

Scientific conferences (ASGCT, AHA, ESGCT) for data dissemination

Disseminating preclinical data at major scientific venues validates the science. Editas Medicine presented preclinical data on its lead candidate, EDIT-401, at several key meetings in late 2025. The oral presentation at the 32nd Annual European Society of Gene and Cell Therapy (ESGCT) Congress (October 7-10, 2025) was led by the Executive Vice President and Chief Scientific Officer, Dr. Linda Burkly. The abstract number for that oral presentation was OR069.

Also, the company presented a moderated digital poster at the American Heart Association (AHA) Scientific Sessions 2025 (November 7-10, 2025). The data presented at both AHA and ESGCT demonstrated over 90% LDL-C reduction in non-human primates with EDIT-401. Earlier in the year, data was presented at the ASGCT annual meeting in May 2025.

Management also used investor conferences as a channel:

• H.C. Wainwright Genetic Medicines Virtual Conference: Fireside Chat on October 14, 2025.
• Chardan 9th Annual Genetic Medicines Conference: Panel Discussion on October 21, 2025.
• 8th Annual Evercore Healthcare Conference: Fireside Chat on December 2, 2025, at 9:10 AM EST.

Regulatory submissions (IND/CTA) to the FDA and other agencies

The path to the clinic is formalized through regulatory filings. Editas Medicine remains on track to submit an Investigational New Drug (IND) or Clinical Trial Application (CTA) for EDIT-401 by mid-2026. The goal is to achieve initial in vivo human proof-of-concept data by year-end 2026.

A key regulatory milestone was already achieved via a partner channel: the first IND/CTA was accepted for the CD19 HD Allo CAR T program, which is part of the collaboration with Bristol Myers Squibb. This acceptance triggered a milestone payment. The company also anticipated establishing one additional target cell type/tissue beyond HSCs and the liver by the end of 2025.

Investor Relations website for corporate and financial updates

The Investor Relations section of www.editasmedicine.com is the primary hub for financial transparency. The company announced its Third Quarter 2025 Results and Business Updates on November 10, 2025, via press release and SEC filings. Importantly, the company stated it does not plan to host quarterly financial results conference calls moving forward.

For public market data as of December 4, 2025, 3:50 PM EST:

Stock Metric	Value
NASDAQ Ticker	EDIT
Closing Price	$2.44
Volume	1,293,645
52 Week High	$4.54
52 Week Low	$0.91
Common Shares Outstanding (Oct 31, 2025)	97,618,660

Webcasts for investor presentations are available live, with archived replays remaining accessible for approximately 30 days following each event.

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Customer Segments

You're looking at the customer base for Editas Medicine, Inc. (EDIT) as of late 2025. This is a company deep in the R&D phase, so the 'customers' aren't buying pills yet; they are partners, patients waiting for breakthroughs, and the capital markets funding the journey. Honestly, the segments reflect this high-risk, high-reward biotech reality.

Large pharmaceutical and biotech companies seeking gene editing assets

This segment is crucial because, right now, their revenue is driven by strategic alliances, not product sales. These larger entities provide the capital and potential commercial scale that Editas Medicine, Inc. needs to advance its pipeline. You can see this dependency clearly in the Q3 2025 results, where Collaboration and other research and development revenues hit $7.5 million, a massive jump from the $0.1 million in the same period in 2024. That surge was tied to a milestone achieved under the collaboration agreement with Bristol Myers Squibb (BMS). Also, the company retains rights under a license agreement with Vertex Pharmaceuticals, which contributes to their extended cash runway. These companies are buying access to Editas Medicine, Inc.'s proprietary CRISPR/Cas12a and Cas9 patent estates for human medicines.

Patients with serious genetic diseases with high unmet need (e.g., high LDL-C)

For patients, the value proposition is a potential one-time, transformative therapy. The lead in vivo development candidate, EDIT-401, targets the reduction of LDL cholesterol (LDL-C). The preclinical data is compelling: it showed a mean LDL-C reduction of >90% in non-human primates, which is significantly better than the 40%-60% mean reduction seen with standard of care therapies. The near-term action for this segment is waiting; Editas Medicine, Inc. is on track to submit the Investigational New Drug (IND) or Clinical Trial Application (CTA) for EDIT-401 by mid-2026, aiming for initial human proof-of-concept data by year-end 2026.

Here's a quick look at the pipeline progress and financial backing supporting this patient focus:

Metric	Value / Date	Relevance
EDIT-401 NHP Efficacy	>90% mean LDL-C reduction	Potential superiority over standard of care (40%-60% reduction)
Cash Runway End Date	Third quarter of 2027	Funds operations through key data milestones
Cash, Cash Equivalents, Marketable Securities (as of 9/30/2025)	$165.6 million	Financial stability for R&D progression
Target IND/CTA Submission for EDIT-401	Mid-2026	Timeline to initiate human trials

Clinical investigators and research hospitals for trials

This group is essential for executing the clinical strategy, especially as Editas Medicine, Inc. pivots to in vivo therapies targeting the liver and hematopoietic stem cells (HSCs). While specific numbers of active trial sites aren't public, their engagement is evidenced by the scientific dissemination activities. For instance, preclinical data for EDIT-401 was presented at the American Heart Association (AHA) Scientific Sessions 2025 and the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress. These presentations are how Editas Medicine, Inc. establishes credibility with the investigators who will eventually run their trials.

Institutional and individual investors in the biotech sector

Investors are buying into the potential of the CRISPR technology and the extended financial runway. As of October 31, 2025, the stock price was $3.08, with a market capitalization of $277M based on 97.6M shares outstanding. The ownership structure shows significant institutional interest; there are 327 institutional owners on file. For example, BlackRock, Inc. held 8,019,891 shares as of September 30, 2025. The market is clearly watching the burn rate; the net loss for Q3 2025 was $25.1 million, though this was narrower than the prior year's loss of $62.1 million. The company is actively managing capital, having raised $17.8 million in gross equity proceeds from its ATM facility during Q3 2025.

Investor sentiment is shaped by key financial and operational milestones:

• Stock price on December 3, 2025: $2.36
• Estimated total revenue for the full 2025 fiscal year: $12.67 million
• Number of institutional investors holding positions: 327
• Total Value of Holdings by major institutions (as of 9/30/2025): $105 million
• Net Loss for Q3 2025: $25.1 million

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Cost Structure

You're looking at the major drains on Editas Medicine, Inc.'s cash reserves as they push their in vivo pipeline forward. For a company like Editas Medicine, the Cost Structure is almost entirely driven by the science.

Dominantly Research and Development (R&D) expenses are the single largest cost component. This covers everything from lab work and discovery to preclinical studies and manufacturing scale-up for their gene editing candidates. The focus has clearly shifted following the discontinuation of the reni-cel program.

The R&D spend shows a significant reduction compared to the prior year, reflecting that strategic pivot. For the third quarter ending September 30, 2025, Research and Development expenses were reported at $19.8 million. That's a sharp drop when you compare it to the $47.6 million incurred in the third quarter of 2024. To give you a broader view of the year-to-date trend, the first quarter of 2025 saw R&D expenses of $26.6 million, down from $48.8 million in Q1 2024.

The cost structure was heavily impacted by one-time charges early in the year. The first quarter of 2025 included significant restructuring and impairment charges totaling $40.9 million. These charges were tied directly to the discontinuation of the reni-cel program, covering workforce reductions and impairment of related equipment. For the nine months ended September 30, 2025, the cumulative restructuring and impairment charges amounted to $66.9 million. To be fair, Editas Medicine did not recognize any restructuring and impairment charges in the third quarter of 2025 itself.

Here's a quick look at the operating expense shift:

• Q3 2025 R&D: $19.8 million
• Q3 2024 R&D: $47.6 million
• Q3 2025 G&A: $12.3 million
• Q3 2024 G&A: $18.1 million

General and administrative costs, which cover corporate overhead, executive salaries, and non-R&D related support functions, also saw a reduction as headcount was streamlined. General and administrative expenses for Q3 2025 were $12.3 million, down from $18.1 million in Q3 2024. This reflects the reduced workforce following the December 2024 program discontinuation.

The final major cost category involves Intellectual property maintenance and licensing fees. Editas Medicine is the exclusive licensee for key CRISPR patent estates from the Broad Institute and Harvard University for human medicines. This means they incur ongoing costs to maintain these licenses, including potential milestone payments, success fees, royalty fees, and patent maintenance costs owed to licensors. While the exact recurring expense for these fees in 2025 isn't itemized separately in the high-level releases, these obligations are contingent upon future development and regulatory success.

You can see the material impact of the strategic shift on operating expenses in this comparison:

Expense Category	Period	Amount (USD)
Restructuring and Impairment Charges	Q1 2025 (Three Months)	$40.9 million
Restructuring and Impairment Charges	Nine Months Ended Sept 30, 2025 (YTD)	$66.9 million
Research and Development Expenses	Q3 2025 (Three Months)	$19.8 million
General and Administrative Expenses	Q3 2025 (Three Months)	$12.3 million

Finance: draft 13-week cash view by Friday.

Editas Medicine, Inc. (EDIT) - Canvas Business Model: Revenue Streams

You're looking at how Editas Medicine, Inc. funds its operations right now, and honestly, it's all about partnerships and hitting specific targets. For a company deep in the R&D phase, revenue isn't coming from selling a commercial product; it's coming from the value embedded in its intellectual property and the success of its collaborators.

The primary source of top-line income is clearly tied to external agreements. For the third quarter ending September 30, 2025, Collaboration and other R&D revenues hit $7.54 million. That number is a huge jump compared to the $0.1 million recognized in the same period of 2024, showing the lumpy, milestone-driven nature of this income.

Here's a quick look at how that Q3 revenue stacks up against the analyst view for the full year:

Metric	Amount
Q3 2025 Collaboration & R&D Revenue	$7.54 million
Analyst-Estimated Full-Year 2025 Revenue	$12.67 million
Q3 2024 Collaboration & R&D Revenue	$0.1 million

What this estimate hides is that the full-year number relies heavily on hitting future milestones, which is standard for this sector. If onboarding takes longer than expected, that full-year projection could shift.

The key drivers for these revenue events are structured around the value of Editas Medicine's gene editing platform:

• Collaboration and other R&D revenues (Q3 2025: $7.54 million).
• Milestone payments from strategic partners, such as the recognition tied to the Bristol Myers Squibb (BMS) collaboration, specifically following an Investigational New Drug (IND) application acceptance for their CD19 HD Allo CAR T program.
• Licensing and sublicensing revenue from foundational CRISPR IP, evidenced by retained payments under the license agreement with Vertex Pharmaceuticals, which contributes to extending the cash runway.

To be fair, the Q3 surge was almost entirely due to one significant event. The increase was primarily attributable to the recognition of revenue related to a milestone achieved under the Company's collaboration agreement with BMS in the third quarter of 2025. This underscores that revenue visibility is low until a specific development or regulatory event occurs.

Finance: draft 13-week cash view by Friday.